Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

被引：0
|
作者：
Eric S. Daar [1 ]
Chloe Orkin [2 ]
Paul E. Sax [3 ]
Debbie Hagins [4 ]
Anton Pozniak [5 ]
Kimberly Workowski [6 ]
Cynthia Brinson [7 ]
Juan Manuel Tiraboschi [8 ]
Hui Liu [9 ]
Chris Deaton [10 ]
Cal Cohen [10 ]
Sharline Madera [10 ]
Jason T. Hindman [10 ]
Moti Ramgopal [10 ]
机构：
[1] Lundquist Institute at Harbor-UCLA Medical Center,
[2] Queen Mary University of London,undefined
[3] Brigham and Women’s Hospital,undefined
[4] Coastal CARE Centers,undefined
[5] Chelsea and Westminster Hospital,undefined
[6] London School of Hygiene and Tropical Medicine,undefined
[7] Emory University,undefined
[8] Central Health,undefined
[9] Hospital Universitari de Bellvitge,undefined
[10] Gilead Sciences,undefined
[11] Inc.,undefined
[12] Midway Research Center and Midway Specialty Care Center,undefined
来源：
AIDS Research and Therapy | / 22卷 / 1期
关键词：
Antiretroviral therapy; Bictegravir; Body mass index; Dolutegravir; Glucose; HIV-1; Tenofovir alafenamide;
D O I：
10.1186/s12981-025-00732-w
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
    Sax, Paul E.
    DeJesus, Edwin
    Crofoot, Gordon
    Ward, Douglas
    Benson, Paul
    Dretler, Robin
    Mills, Anthony
    Brinson, Cynthia
    Wei, Xuelian
    Collins, Sean E.
    Cheng, Andrew
    AIDS, 2018, 32 (12) : 1723 - 1725
  • [2] Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide
    Tan, Darrell H. S.
    Antinori, Andrea
    Eu, Beng
    Galindo Puerto, Maria Jose
    Kinder, Clifford
    Sweet, Donna
    Van Dam, Cornelius N.
    Sutton, Kenneth
    Sutherland-Phillips, Denise
    Berni, Alessandro
    Zhang, Feifan
    Urbaityte, Rimgaile
    Baugh, Bryan
    Spreen, William
    van Wyk, Jean
    Garges, Harmony P.
    Patel, Parul
    Batterham, Rachel
    D'Amico, Ronald
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2025, 98 (04) : 401 - 409
  • [3] Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir and abacavir/lamivudine OVERRIDE
    Ustianowski, A.
    Molina, J-M
    Ward, D.
    Stellbrink, H. J.
    Podzamczer, D.
    Brinson, C.
    Custodio, J.
    Liu, H.
    Andreatte, K.
    Martin, H.
    Quirk, E.
    HIV MEDICINE, 2018, 19 : S29 - S30
  • [4] Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy
    Orkin, Chloe
    Antinori, Andrea
    Rockstroh, Juergen K.
    Moreno-Guillen, Santiago
    Martorell, Claudia T.
    Molina, Jean-Michel
    Lazzarin, Adriano
    Maggiolo, Franco
    Yazdanpanah, Yazdan
    Andreatta, Kristen
    Huang, Hailin
    Hindman, Jason T.
    Martin, Hal
    Pozniak, Anton
    AIDS, 2024, 38 (07) : 983 - 991
  • [5] Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort
    Ciccullo, Arturo
    Baldin, Gianmaria
    Cervo, Adriana
    Moschese, Davide
    Lagi, Filippo
    Cossu, Maria Vittoria
    Grimaldi, Alessandro
    Giacomelli, Andrea
    Rusconi, Stefano
    Sterrantino, Gaetana
    Borghetti, Alberto
    Antinori, Spinello
    Mussini, Cristina
    Di Giambenedetto, Simona
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 80 (01) : 175 - 177
  • [6] Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV
    Tempestilli, Massimo
    D'Avolio, Antonio
    De Nicolo, Amedeo
    Agrati, Chiara
    Antinori, Andrea
    Cicalini, Stefania
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (12) : 3320 - 3322
  • [7] Immune and metabolic profile in people living with HIV initiating emtricitabine/tenofovir alafenamide/bictegravir
    Squillace, Nicola
    Ricci, Elena Delfina
    Maggi, Paolo
    Taramasso, Lucia
    Menzaghi, Barbara
    De Socio, Giuseppe Vittorio
    Sarchi, Eleonora
    Piconi, Stefania
    Pellicano, Giovanni Francesco
    Madeddu, Giordano
    Bandera, Alessandra
    Martini, Salvatore
    Celesia, Benedetto Maurizio
    Orofino, Giancarlo
    Ferrara, Sergio
    Pontali, Emanuele
    Carleo, Maria Aurora
    Salomoni, Elena
    Cenderello, Giovanni
    Cascio, Antonio
    Angioni, Goffredo
    Falasca, Katia
    Bargiacchi, Olivia
    Di Biagio, Antonio
    Bonfanti, Paolo
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 271 - 273
  • [8] Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
    Corona, Diana
    Perez-Valero, Ignacio
    Camacho, Angela
    Liarte, Angela Gutierrez
    Montero-Alonso, Marta
    Aleman, Maria Remedios
    Ruiz-Seco, Pilar
    Gonzalez, Alexandre Perez
    Riera, Melchor
    Jarrin, Inmaculada
    Rivero-Juarez, Antonio
    Rivero, Antonio
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (01)
  • [9] Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
    Emma D. Deeks
    Drugs, 2018, 78 : 1817 - 1828
  • [10] ECONOMIC AND ORGANIZATIONAL ADVANTAGES OF BICTEGRAVIR/ALAFENAMIDE TENOFOVIR/EMTRICITABINE FOR HIV TREATMENT
    Ferrario, L. B.
    Menzaghi, B.
    Rizzardini, G.
    Bellavia, D.
    Schettini, F.
    Garagiola, E.
    Foglia, E.
    VALUE IN HEALTH, 2024, 27 (12) : S96 - S96
12345